Drug Trial Radar · NCT04692493
RA-PRO PRAGMATIC TRIAL
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
924
Planned (sponsor's estimate)
Start
Sep 22, 2021
Primary completion
May 31, 2029
Study completion Jul 31, 2029
Sponsor
- Lead sponsor
- University of Alabama at BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Patient-Centered Outcomes Research Institute
- First posted
- Dec 31, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another TNFi-biologic, i.e., a second TNFi-biologic first. This is not based on solid evidence, but on arbitrary algorithms often proposed by health insurance plans, and/or physician experience and habit (TNFis launched 22 yrs ago vs. the first tsDMARD 8 years ago vs. first non-TNF-biologic launched 17 years ago). This study will fill a critical knowledge gap by generating CER data for important PROs between these treatment options, switching to a non-TNFi biologic or a tsDMARD in patients with active RA despite the use of a TNFi-biologic.
Conditions
- Rheumatoid Arthritis
Interventions
targeted synthetic DMARD classDrug
Switching to a targeted synthetic DMARD (choice from targeted synthetic DMARDs; currently available are tofacitinib, baricitinib, upadacitinib) in people with active RA despite current treatment
non-TNFi-biologic classDrug
Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite current treatment,
Primary outcomes
What the sponsor says the trial is designed to measure.
- Functional LimitationTime frame: Change from baseline to 12 months
Locations
49 sites in 2 countries. Site status is shown where the registry gives one.
East Alabama Arthritis Center PC
Auburn, Alabama · Recruiting
Bendcare, LLC
Birmingham, Alabama · Recruiting
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
SunValley Arthritis Center, Ltd
Peoria, Arizona · Recruiting
University of Arizona
Tucson, Arizona · Recruiting
Pacific Arthritis Care Center
Los Angeles, California · Recruiting
University of California, Los Angeles
Los Angeles, California · Recruiting
Arthritis Medical Center
Nipomo, California · Recruiting
Turlock Arthritis & Osteoporosis Center,
Turlock, California · Recruiting
Center for Rheumatology Research
Woodland Hills, California · Recruiting
George Munoz MD, PC
Aventura, Florida · Recruiting
American Arthritis and Rheumatology Associates LLC
Clearwater, Florida · Recruiting
CZ Rheumatology
Coral Springs, Florida · Recruiting
American Arthritis and Rheumatology Associates LLC
Fort Lauderdale, Florida · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
Palm Beach Rheumatology and Wellness
Jupiter, Florida · Recruiting
Arthritis & Rheumatology Center of South Florida
Margate, Florida · Recruiting
Life Medical Research Group
Miami Gardens, Florida · Recruiting
Southwest Florida Rheumatology
Riverview, Florida · Recruiting
Southeast Georgia Physician Associates-Rheumatology
Brunswick, Georgia · Recruiting
Indiana University Health
Carmel, Indiana · Recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
Tufts University
Boston, Massachusetts · Recruiting
University of Massachusetts Chan Medical School
Worcester, Massachusetts · Recruiting
American Arthritis and Rheumatology Associates -Mi PLLC
Okemos, Michigan · Recruiting
Saint Paul Rheumatology, P.A.
Eagan, Minnesota · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
Dr. Jayashree Sinha
Clovis, New Mexico · Recruiting
Inspire Santa Fe Medical Group
Santa Fe, New Mexico · Recruiting
New York University
New York, New York · Recruiting
Hospital for Special Surgery
New York, New York · Recruiting
University Hospital Cleveland Medical Ctr
Cleveland, Ohio · Recruiting
The MetroHealth System
Cleveland, Ohio · Recruiting
Arthritis and Rheumatology of Southwest Ohio
Liberty Township, Ohio · Recruiting
Southern Ohio Rheumatology
Wheelersburg, Ohio · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
Altoona Center for Clinical Research
Duncansville, Pennsylvania · Recruiting
Rheumatology and Arthritis Care Center
Exton, Pennsylvania · Recruiting
Allegheny Health Network
Pittsburgh, Pennsylvania · Recruiting
PA Regional Center for Arthritis and Osteoporosis Research
Wyomissing, Pennsylvania · Recruiting
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.